No TRACER the sweet spot for vorapaxar in ACS
This article was originally published in Scrip
Executive Summary
The implications of Merck & Co's unexpected premature closure in January of the Phase III TRACER study of vorapaxar became clearer this weekend as the full data from the failed study were presented at the American Heart Association meeting and published in the New England Journal of Medicine.